| Compounda |
Edema weight (X ± SD mg) |
Inhibition ratio (%) |
| CMC |
7.6±2.8 |
31.8±23.9 |
| Aspirin |
0.9±0.6 |
89.5±7.0c |
| 5 |
3.5±2.2 |
64.3±23.0b |
| 9a |
1.2±1.1 |
87.5±11.8c |
| 9b |
2.6±1.6 |
78.5±13.1b |
| 9c |
1.7±1.1 |
86.8±9.0c |
| 10a-α |
1.9±1.5 |
84.5±12.1b |
| 10a-β |
2.0±1.4 |
81.1±15.7b |
| 10b |
1.6±1.3 |
86.7±10.5c |
| 10c |
1.2±0.9 |
90.7±7.1c |
| 11a |
2.4±1.4 |
82.6±11.0b |
| 11b |
1.9±1.3 |
85.7±9.9c |
| 11c |
1.7±0.8 |
86.9±6.3c |
|
cAspirin=Positive control, CMC=Vehicle, Dose of mimetic peptides derivatives=10 μmol/kg,
dose of aspirin = 100 mg/kg; n = 12.
bCompared to CMC p<0.01.
cCompared to CMC p<0.01, Compared to 5 p<0.05. |
| Table 2: Anti-inflammatory activities of glucosamine mimetic peptides derivatives determined using an xylene-induced ear edema model. |